Karen Mather
Nurse Practitioner · Bethany Beach, DENPI 1285250118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$592
- AbbVie$349
- Novo Nordisk$230
- Boehringer Ingelheim$215
- Amgen$215
- Eisai Inc.$211
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 48 | $592 |
| AbbVie | 16 | $349 |
| Novo Nordisk | 12 | $230 |
| Boehringer Ingelheim | 3 | $215 |
| Amgen | 12 | $215 |
| Eisai Inc. | 6 | $211 |
| Lundbeck LLC | 11 | $197 |
| Lilly USA, LLC | 8 | $194 |
| Teva Pharmaceuticals USA, Inc. | 6 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Idorsia Pharmaceuticals US Inc | 3 | $115 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| Astellas Pharma US Inc | 6 | $99 |
| Exact Sciences | 5 | $96 |
| Pfizer | 4 | $91 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Sunovion Pharmaceuticals Inc. | 4 | $74 |
| Mylan Specialty L.p. | 2 | $68 |
| AstraZeneca | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Abbott | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Bayer | 2 | $31 |
| GSK | 2 | $28 |
| Johnson & Johnson | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,576 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $67,351 |
| MounjaroTirzepatide | 22 | $24,708 |
| SynthroidLevothyroxine Sodium | 24 | $2,943 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,361 |
| Rosuvastatin Calcium | 103 | $1,360 |
| Ezetimibe | 29 | $1,277 |
| Bupropion XlBupropion Hcl | 25 | $1,215 |
| Levothyroxine Sodium | 73 | $1,076 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 25 | $1,033 |
| Ofloxacin | 30 | $1,010 |
| Alprazolam | 141 | $801 |
| Atorvastatin Calcium | 75 | $674 |
| Zolpidem Tartrate | 90 | $669 |
| Tramadol Hcl | 142 | $664 |
| Methylprednisolone | 74 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $67,35156 claims |
| Lilly USA, LLCMounjaro | $194 | $24,70822 claims |
| AbbVieSynthroid | $349 | $2,94324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Bethany Beach
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
- Kathleen HudsonMillville$10K
- Nancy Townsend O'DayMillsboro$8K
- Funmilola OlaoyeNewark$7K
- Monica SamWilmington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.